α1-antitrypsin deficiency (AATD) remains the only readily identified genetic cause of chronic obstructive pulmonary disease (COPD). Furthermore, there is growing evidence that even a moderate deficiency increases the risk of lung disease among smokers. Despite these facts, the uptake of testing for AATD in at-risk populations remains low for many reasons, and a lack of clarity among clinicians regarding the most appropriate diagnostic techniques presents a major deterrent.
This 2019 guide for α1-antitrypsin deficiency testing addresses the benefits of A1AT diagnosis, the technical basis of the available diagnostic methods. A1AT phenotyping by isolectric focusing is part of the available diagnostic methods and it allows detection of multiple variants of A1AT in one assay.
The topics covered should equip clinicians with the core knowledge required to confidently assess patients for AATD and increase the number of AATD testing.
Test associated with this resource
Related instrument
L’automazione compatta e conveniente dell’elettroforesi capillare.
L’evoluzione fa la differenza.
Un concentrato dell’esperienza di Sebia in uno strumento ad alta produttività.
Discover more resources on Alpha-1 Antitrypsin Deficiency
Questa sezione contiene informazioni destinate a un'ampia diffusione e potrebbe pertanto includere dettagli sui prodotti o informazioni non disponibili o non valide nel proprio Paese. Si prega di contattare il rappresentante Sebia di zona. Informazioni destinate agli operatori sanitari. Leggere attentamente le istruzioni riportate nei foglietti illustrativi dei reagenti e nei manuali degli strumenti.